Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant

NCT03380962 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Kidney Failure, Chronic
End-Stage Renal Disease
Transplant Glomerulopathy
Transplant;Failure,Kidney
Kidney Transplant Failure and Rejection
Antibody-mediated Rejection
Kidney Transplant; Complications

Interventions

DRUG: Clazakizumab

Sponsor

Stanley Jordan, MD